[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Li et al., 2016 - Google Patents

Immuno-targeting the multifunctional CD38 using nanobody

Li et al., 2016

View HTML
Document ID
4886511292459131888
Author
Li T
Qi S
Unger M
Hou Y
Deng Q
Liu J
Lam C
Wang X
Xin D
Zhang P
Koch-Nolte F
Hao Q
Zhang H
Lee H
Zhao Y
Publication year
Publication venue
Scientific Reports

External Links

Snippet

CD38, as a cell surface antigen is highly expressed in several hematologic malignancies including multiple myeloma (MM) and has been proven to be a good target for immunotherapy of the disease. CD38 is also a signaling enzyme responsible for the …
Continue reading at www.nature.com (HTML) (other versions)

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/574—Immunoassay; Biospecific binding assay for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere

Similar Documents

Publication Publication Date Title
Li et al. Immuno-targeting the multifunctional CD38 using nanobody
Zhang et al. B7-H3-targeted CAR-T cells exhibit potent antitumor effects on hematologic and solid tumors
Tan et al. An unexpected N-terminal loop in PD-1 dominates binding by nivolumab
Giordano-Attianese et al. A computationally designed chimeric antigen receptor provides a small-molecule safety switch for T-cell therapy
Ereño-Orbea et al. Molecular basis of human CD22 function and therapeutic targeting
Chang et al. Rewiring T-cell responses to soluble factors with chimeric antigen receptors
Zhang et al. Structure of the full-length glucagon class B G-protein-coupled receptor
McNally et al. Retriever is a multiprotein complex for retromer-independent endosomal cargo recycling
Im et al. Structure of the dopamine D2 receptor in complex with the antipsychotic drug spiperone
Thomas et al. Framework engineering to produce dominant T cell receptors with enhanced antigen-specific function
Marjon et al. Tetraspanin CD82 regulates bone marrow homing of acute myeloid leukemia by modulating the molecular organization of N-cadherin
Liu et al. Cytosolic interaction of type III human CD38 with CIB1 modulates cellular cyclic ADP-ribose levels
Banaszek et al. On-target restoration of a split T cell-engaging antibody for precision immunotherapy
Donaldson et al. Identification and grafting of a unique peptide-binding site in the Fab framework of monoclonal antibodies
Hart et al. Structure of AMH bound to AMHR2 provides insight into a unique signaling pair in the TGF-β family
Bardhan et al. Phosphorylation of PD-1-Y248 is a marker of PD-1-mediated inhibitory function in human T cells
Hu et al. Structural basis for human PECAM-1-mediated trans-homophilic cell adhesion
Schwartz et al. Characterization of sabatolimab, a novel immunotherapy with immuno-myeloid activity directed against TIM-3 receptor
Tomita et al. Protein cell‐surface display through in situ enzymatic modification of proteins with a poly (Ethylene glycol)‐lipid
Maruta et al. Direct comparison of target-reactivity and cross-reactivity induced by CAR-and BiTE-redirected T cells for the development of antibody-based T-cell therapy
Jia et al. A humanized anti-DLL4 antibody promotes dysfunctional angiogenesis and inhibits breast tumor growth
Gopalakrishnan et al. A novel luciferase-based assay for the detection of chimeric antigen receptors
Fitting et al. Phage display-based generation of novel internalizing antibody fragments for immunotoxin-based treatment of acute myeloid leukemia
Lesne et al. Structural basis for chemically-induced homodimerization of a single domain antibody
Cha et al. Ephrin receptor A10 monoclonal antibodies and the derived chimeric antigen receptor T cells exert an antitumor response in mouse models of triple-negative breast cancer